Topics

Gilead Sciences Inc.
U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug
U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug

Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000 per treatment course, raising renewed concerns over the high costs to taxpayers. In a letter sent Friday, Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa) asked Gilead to explain why the high U.S. price — $1,000 a pill — for the drug Sovaldi differs from that in other countries as well as from a previous U.S. estimate. Pharmasset, the drug's original developer, priced the treatment at $36,000, the senators wrote, citing documents filed with the Securities and Exchange Commission. Gilead acquired Pharmasset in 2012 for $11 billion. Sovaldi sales...

Loading